New application of P53 gene

A new application, P53 protein technology, applied in gene therapy, medical preparations containing active ingredients, metabolic diseases, etc., can solve the problems of insulin deficiency, poor insulin effect, etc., to achieve short production cycle, easy control of process conditions, Simple production process

Active Publication Date: 2013-01-30
张跃伟
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In people with type 2 diabetes, the ability to produce insulin in the body is not completely lost, and some patients even produce too much insulin in the body, but the effect of insulin is poor, so the insulin in the body of the patient may be in a state of relative deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of P53 gene
  • New application of P53 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1. Material

[0021] 1. Test substance: Recombinant human P53 adenovirus injection, National Medicine Standard S20040004, main ingredients: Recombinant adenovirus-P53 gene particles; Excipients: trihydroxyaminomethane, glycerol. Specification: 1×10 12 VP / support. Purchased from a commercially available recombinant human P53 adenovirus injection, produced by Shenzhen Sibio Gene Technology Co., Ltd., batch number: 20070901.

[0022] 2. Animals:

[0023] db / db mouse: Type 2 diabetes mouse model, purchased from Nanjing Pengsheng Biotechnology Development Co., Ltd., to study the hypoglycemic effect of p53 gene.

[0024] db / m mice: purchased from Nanjing Pengsheng Biotechnology Development Co., Ltd., as a control group of normal mice.

[0025] Two, method

[0026] Fifty 6-week-old db / db mice with a weight of 45.8±3.3g were randomly divided into five groups, each with 10 mice, namely the p53 gene low-dose group, p53 gene high-dose group, pioglitazone group, adenovirus group, and model ...

Embodiment 2

[0045] 1. Material

[0046] 1. Test substance: Recombinant human P53 adenovirus injection, National Medicine Standard S20040004, main ingredients: Recombinant adenovirus-P53 gene particles; Excipients: trihydroxyaminomethane, glycerol. Specification: 1×10 12 VP / support. Purchased from a commercially available recombinant human P53 adenovirus injection, produced by Shenzhen Sibio Gene Technology Co., Ltd., batch number: 20070901.

[0047] 2. Treat the crowd

[0048] There were 6 patients with type 2 diabetes, all male, aged 43-76 years old, with an average of 56.7 years old. Fasting blood glucose was 8.9~12.3umol / L, with an average of 10.6umol / L. All patients were treated with insulin. The application time of insulin was 1 to 5 years, with an average of 2.6 years. The insulin dosage was 12u~48u, and the average daily dosage was 26u.

[0049] Before treatment, the patient signs a consent form for the use of special medications.

[0050] Treatment method: Recombinant human P53 adenoviru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses new application of a p53 gene, and particularly relates to application of the P53 gene in preparation of a drug for treatment of glucose metabolism abnormality diseases, belonging to the field of bio-pharmaceuticals. In the embodiment, a db / db rat is used as a research object to prove good hypoglycemic effects of the p53 gene. Moreover, six patients with Type II diabetes are treated, and the same significant curative effect can be achieved. In combination with results of study at the diabetes pathogenesis gene level in recent years and use of the p53 gene as a controlling gene for a key abnormal gene in the body, correction of abnormal glucose metabolism can be realized by regulating a gene encoding method corresponding to a relevant regulatory factor in the process of abnormal glucose metabolism. The problem of genetic treatment of glucose metabolism abnormality diseases can be solved, and the p53 gene has broad application prospects in treatment of diabetes.

Description

Technical field [0001] The invention belongs to the field of biopharmaceuticals, and relates to the new application of P53 gene, and more specifically relates to the application of P53 gene in the preparation of drugs for treating abnormal blood glucose metabolism diseases. Background technique [0002] As an important tumor suppressor gene, P53 gene has been extensively studied by scholars from various countries for more than 30 years. According to reports, about half of human cancers are caused by mutation and inactivation of this gene. The P53 gene is named after it encodes a protein with a molecular weight of 53kDa. The expression product is gene regulatory protein (P53 protein). When DNA is damaged, the expression product increases sharply, which can inhibit the further operation of the cell cycle. Once the P53 gene is mutated, the P53 protein will be inactivated, cell division will lose control, and the body will become cancerous. Therefore, p53 can make cancer cells suic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K38/17A61P3/10
Inventor 张跃伟
Owner 张跃伟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap